Has Elizabeth Schmidt, PA received payments from drug or device companies?

Yes. Drug and device makers reported $6,029 in general payments to Elizabeth Schmidt, PA across 405 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elizabeth Schmidt, PA did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elizabeth Schmidt, PA come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elizabeth Schmidt, PA

Medical · Salem, ORNPI 1972048700

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 33.3% of the total. Among medical clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,029in general payments, 2019–2025

Across 405 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Johnson & Johnson$2K
Novartis$529
Sanofi$453
Lilly USA, LLC$375
Regeneron Healthcare Solutions, Inc.$280
plus $702 from 11 others

What the payments were for

Food & beverage$5,45490%
Education$57510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	158	$2,006
Johnson & Johnson	118	$1,685
Novartis	32	$529
Sanofi	29	$453
Lilly USA, LLC	23	$375
Regeneron Healthcare Solutions, Inc.	13	$280
Sanofi-aventis U.S. LLC	2	$179
UCB, Inc.	6	$133
E.r. Squibb & Sons, L.L.C.	3	$93
Biofrontera Inc.	9	$74
Incyte Corporation	2	$48
Pfizer	2	$37
Sun Pharmaceutical Industries Inc.	2	$35
Galderma Laboratories, L.p.	2	$35
Amgen	2	$28
Smith+Nephew	1	$27
LEO Pharma Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$110

How this compares

$6,029 in reported general payments places this provider in the 95th percentile of 364 medical providers in Oregon.

See all medical providers in Oregon →

Medicare billing

Part B allowed, 2024

$253,876

Medicare patients

792

Services billed

6,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Skyrizi PenRisankizumab-Rzaa	24	$499,152
Dupixent PenDupilumab	63	$252,670
Humira(Cf) PenAdalimumab	12	$119,358
RinvoqUpadacitinib	11	$80,711
Fluorouracil	102	$5,471
Clobetasol Propionate	106	$4,218
Mometasone Furoate	99	$2,356
Triamcinolone Acetonide	150	$1,583
Doxycycline Monohydrate	66	$1,509
Tretinoin	17	$1,279
Dutasteride	17	$1,266
Mupirocin	141	$1,144
Metronidazole	33	$998
Tacrolimus	13	$984
Ketoconazole	46	$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRinvoq	$2,006	$80,71111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 364 medical providers in Oregon.

Other medical in Salem

See the full list for Oregon →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →